Circulating tumour DNA (ctDNA) is tumour-deriver fragmented DNA which originates either directly from the tumour or from circulating tumour cells. Identifying and quantifying ctDNA in patient blood can aid in detecting, diagnosing, and monitoring a tumour or can guide and assess the efficacy of tumour-specific treatments.
Analysis remains challenging for this type of molecule because it requires high sensitivity and selectivity for target genes.
In this webinar, Dr. Kurt Sales, Chief Scientific Officer at Agilex Biolabs, will discuss analytical hurdles and platform compatibility with ctDNA detection and quantification. Illustrating the importance of platform choice in a bioanalytical approach, Dr. Sales will present a case study of our successful detection of exon 15 (V600E) of the B-Raf proto-oncogene (BRAF) using Digital Droplet PCR (ddPCR).
Dr. Kurt Sales has over 25 years of experience in a career spanning research and development, early drug discovery, and regulated bioanalysis across preclinical and clinical drug development. At Agilex Biolabs, Kurt is Chief Scientific Officer, responsible for scientific integrity and strategic research and development.
Kurt has extensive expertise in pre-clinical and clinical assay development, cellular and molecular biology, molecular signaling, flow cytometry, cell-based models, and biomarkers, notably in the areas of inflammation and immunology. Widely published with 45 peer-reviewed scientific papers in high-impact journals, book chapters, and presentations at over 30 conferences, he also has extensive experience ensuring strict GLP compliance for bioanalytical assays and preclinical safety testing through PK/PD/Biomarker assays.
Kurt has a Ph.D. in Medical Biochemistry, a Masters in Biochemistry, a Bachelors of Science in Medicine with Honours in Pharmacology, and a Bachelor of Science in Biochemistry and Physiology. He has a Diploma in Business Organisation and Management and a Post Graduate Certificate in Management.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.